DRRX - DURECT Corporation
After hours:
Chart Events
Intermediate-term KST
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 5.94 |
| Open | 6.02 |
| Bid | 6.00 x 800 |
| Ask | 6.40 x 1100 |
| Day's Range | 5.76 - 6.37 |
| 52 Week Range | 3.17 - 9.70 |
| Volume | |
| Avg. Volume | 126,095 |
| Market Cap | 147.429M |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.61 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.25 |
Fair Value
Related Research
ZacksWall Street Analysts Think Durect (DRRX) Could Surge 594.98%: Read This Before Placing a Bet
The mean of analysts' price targets for Durect (DRRX) points to a 595% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ZacksDurect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
Durect (DRRX) delivered earnings and revenue surprises of -4% and 41.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
PR NewswireDURECT Corporation Reports First Quarter 2023 Financial Results and Business Update
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2023 and provided a corporate update.
- PR Newswire
DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8
- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday, May 8, 2023.
- PR Newswire
DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis
DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader ("KOL") event on Alcohol-Associated Hepatitis on May 16th in New York City. Topics of discussion will include the etiology and prevalence of alcohol-associated hepatitis (AH), current treatment insufficiencies and unmet need for patients with AH, biology of larsucosterol, trial design and status update for the Phase 2b AHFIRM trial in AH, and a company update on regulatory and commercial efforts ongoing for larsu
PR NewswireDURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce, Managing Director, Senior Biotechnology Research Analyst, H.C Wainwright & Co., LLC at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023.
PR NewswireDURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis
DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic modulator programs for the treatment of acute organ injury and chronic liver diseases, today announced that additional data from the company's previously completed Phase 2a trial evaluating larsucosterol in alcohol-associated hepatitis (AH) has been accepted by the peer-reviewed journal American Journal of Gastroenterology. In addition to previously reported safety and efficacy data from the 19-patien
InvestorPlace7 Biotech Stocks Sitting in the Sweet Spot
Biotech stocks aren’t for everyone. They require some additional research and as an investor you have to be comfortable having product pipelines with a long pathway to market. Biotech companies can pour millions into research and development and have nothing to show with it. Biotech companies are on the leading edge of scientific innovation, and they bring in massive profits if they develop a drug that’s deemed to be safe and marketable. Small biotech companies that have potentially attractive d
PR NewswireDURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board
DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023. Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires.
Insider MonkeyDURECT Corporation (NASDAQ:DRRX) Q4 2022 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX) Q4 2022 Earnings Call Transcript March 7, 2023 Operator: Greetings, and welcome to the DURECT Corporation Fourth Quarter 2022 Earnings Call. . I will now turn the conference over to our host, Tim Papp, Chief Financial Officer. Thank you. You may begin. Timothy Papp: Good afternoon, and welcome to DURECT Corporation’s Fourth […]
PR NewswireDURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will participate in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15th, 2023.
ZacksDurect (DRRX) Reports Q4 Loss, Tops Revenue Estimates
Durect (DRRX) delivered earnings and revenue surprises of 13.21% and 2.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
PR NewswireDURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2022 and provided a corporate update.
PR NewswireDURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7
DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market close on Tuesday, March 7, 2023.
InvestorPlace7 Stocks Under $10 to Buy in February
As an investor, you can get some amazing deals in the stock market. You can even fund some great stocks under $10 to buy if you know where to look. What’s the attraction to buying a stock under $10? Well, not everyone likes to spend $100 or more on a large-cap stock that carries a big price tag. Buying a stock under $10 means that for that same $100 you can pick up 10 shares instead of just one. Generally, stocks under $10 to buy are more likely to be growth stocks with longer runways to provide
PR NewswireDURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants
DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor and an existing institutional investor for the purchase and sale of an aggregate of 1,700,000 shares of common stock and, in lieu of shares of common stock, pre-funded warrants to purchase 3
ZacksDurect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?
Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PR NewswireDURECT Announces 1-for-10 Reverse Stock Split
DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT's board of directors today determined that the Company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m. Eastern Time on December 5, 2022. Beginning with the opening of trading on December 6, 2022, the Company's common stock will trade on a split-adjusted basis.
ZacksDurect (DRRX) Reports Q3 Loss, Misses Revenue Estimates
Durect (DRRX) delivered earnings and revenue surprises of 0% and 11.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PR NewswireDURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2022 and provided a corporate update.
PR NewswireDURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2
DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the market close on Wednesday, November 2, 2022.
PR NewswireDURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial
DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, today announced the enrollment of more than 200 of the planned 300 patients in its Phase 2b AHFIRM trial. The AHFIRM trial seeks to evaluate larsucosterol's potential to serve as a treatment for severe alcohol-associated hepatitis (AH).
PR NewswireInnocoll and DURECT Announce U.S. launch of POSIMIR®
Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology company and portfolio business of Gurnet Point Capital, and DURECT Corporation (Nasdaq: DRRX) today announced the recent commercial launch of POSIMIR® (bupivacaine solution) in the United States. POSIMIR is an FDA-approved non-opioid, sustained-release local analgesic for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery.
PR NewswireDURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO will be presenting virtually at the H.C. Wainwright 24th annual Global Investment Conference.